Total Payments
$67,999
2024 Payments
$14,653
Companies
9
Transactions
36
Medicare Patients
2,681
Medicare Billing
$941,304
Payment Breakdown by Category
Consulting$59,192 (87.0%)
Travel$8,015 (11.8%)
Other$452.05 (0.7%)
Food & Beverage$340.50 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $59,192 | 22 | 87.0% |
| Travel and Lodging | $8,015 | 6 | 11.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $452.05 | 2 | 0.7% |
| Food and Beverage | $340.50 | 6 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30,866 | 18 | $0 (2024) |
| BeiGene USA, Inc. | $14,107 | 2 | $0 (2024) |
| Astellas Pharma US Inc | $7,277 | 4 | $0 (2021) |
| Daiichi Sankyo Inc. | $4,908 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,050 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $2,740 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $2,625 | 2 | $0 (2022) |
| Amgen Inc. | $973.50 | 1 | $0 (2022) |
| F. Hoffmann-La Roche AG | $452.05 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,653 | 7 | Merck Sharp & Dohme LLC ($8,083) |
| 2023 | $3,965 | 2 | Merck Sharp & Dohme LLC ($3,965) |
| 2022 | $15,106 | 4 | BeiGene USA, Inc. ($10,732) |
| 2021 | $4,749 | 3 | Astellas Pharma US Inc ($2,061) |
| 2020 | $6,790 | 3 | E.R. Squibb & Sons, L.L.C. ($4,050) |
| 2019 | $15,994 | 10 | Merck Sharp & Dohme Corporation ($15,994) |
| 2018 | $1,526 | 4 | Merck Sharp & Dohme Corporation ($1,074) |
| 2017 | $5,216 | 3 | Astellas Pharma US Inc ($5,216) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $4,117.50 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 02/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 02/14/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 01/19/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $70.95 | General |
| 11/22/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| 05/05/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 11/17/2022 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| 09/13/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $10,732.26 | General |
| Category: Oncology | ||||||
| 05/23/2022 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $973.50 | General |
| 02/17/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 04/14/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2021 | Astellas Pharma US Inc | — | Consulting Fee | Cash or cash equivalent | $2,061.25 | General |
| 12/07/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 11/17/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 01/13/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 06/24/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| 06/24/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 05/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $7,237.03 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $165.89 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $98.91 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 411 | 4,472 | $562,953 | $145,425 |
| 2022 | 21 | 608 | 9,041 | $753,372 | $194,539 |
| 2021 | 27 | 819 | 17,494 | $1.0M | $335,028 |
| 2020 | 27 | 843 | 18,653 | $860,425 | $266,312 |
Total Patients
2,681
Total Services
49,660
Medicare Billing
$941,304
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 3,200 | $401,133 | $112,375 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 102 | $45,390 | $14,444 | 31.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 69 | 76 | $56,088 | $7,907 | 14.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $9,648 | $2,768 | 28.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 25 | 66 | $6,270 | $1,666 | 26.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 49 | 99 | $13,563 | $1,238 | 9.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 12 | $2,520 | $1,214 | 48.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 21 | $7,350 | $1,099 | 15.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 18 | $5,022 | $1,067 | 21.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 13 | 21 | $4,095 | $494.37 | 12.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 17 | $3,043 | $422.61 | 13.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 16 | $2,688 | $364.67 | 13.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 17 | $1,343 | $193.28 | 14.4% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 150 | $1,700 | $109.95 | 6.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 28 | 314 | $1,139 | $30.70 | 2.7% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 34 | 312 | $1,400 | $24.18 | 1.7% |
| J3490 | Unclassified drugs | Office | 2023 | 13 | 15 | $562.00 | $7.32 | 1.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 16 | 3,600 | $505,363 | $143,764 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 45 | 90 | $40,050 | $12,433 | 31.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 93 | 106 | $75,578 | $11,870 | 15.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 14 | 62 | $22,618 | $8,293 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $11,457 | $3,296 | 28.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2022 | 11 | 13 | $9,477 | $2,743 | 28.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 33 | 92 | $8,740 | $2,328 | 26.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 32 | 40 | $13,520 | $2,179 | 16.1% |
About Dr. Harry Yoon, M.D
Dr. Harry Yoon, M.D is a Hematology & Oncology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255408258.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harry Yoon, M.D has received a total of $67,999 in payments from pharmaceutical and medical device companies, with $14,653 received in 2024. These payments were reported across 36 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($59,192).
As a Medicare-enrolled provider, Yoon has provided services to 2,681 Medicare beneficiaries, totaling 49,660 services with total Medicare billing of $941,304. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Internal Medicine
- Location Rochester, MN
- Active Since 11/29/2006
- Last Updated 08/21/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255408258
Products in Payments
- KEYTRUDA (Biological) $17,616
- BRUKINSA (Drug) $10,732
- Developmental Compound $5,216
- TEVIMBRA (Drug) $3,375
- OPDIVO (Biological) $2,250
- ENHERTU (Drug) $1,713
- TECENTRIQ (Biological) $452.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028